Pioglitazone News and Research

RSS

Newer treatment for type 2 diabetes reduces liver fat in patients with NAFLD

In people with type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) is common and can progress to a severe liver disease known as nonalcoholic steatohepatitis (NASH).

19 Mar 2018

Experimental diabetes drugs can make cancer cells vulnerable to chemotherapy agents

Scientists at Dana-Farber Cancer Institute have shown that experimental diabetes drugs can make cancer cells more vulnerable to traditional chemotherapy agents, and they say such combinations should be explored to potentially improve outcomes for cancer patients.

2 Jan 2018

Diabetes patients least likely to follow medical advice regarding medication due to side effects

Diabetes patients who take the most commonly prescribed diabetes drug, metformin, are the least likely to follow medical advice regarding their medication due its side effects, a new article in the journal Diabetes, Obesity and Metabolism reports.

18 Dec 2017

Researchers highlight need for paradigm shift in management of type 2 diabetes

Heart disease is a leading cause of death worldwide and exacerbated by type 2 diabetes, yet diabetes treatment regimens tend to focus primarily on blood sugar maintenance.

21 Jun 2017

Treating PCOS in adolescent girls may help prevent future subfertility, research suggests

In adolescent girls with polycystic ovary syndrome (PCOS), bringing the amount of abdominal visceral fat and liver fat down to normal restores ovulation, normalizes the symptoms of androgen excess, and may help prevent future subfertility, new research from Spain suggests.

4 Apr 2017

Type 2 diabetes drug may someday help combat breast and ovarian cancers

A drug used now to treat Type 2 diabetes may someday help beat breast and ovarian cancers, but not until researchers decode the complex interactions that in some cases help promote tumors, according to Rice University scientists.

30 Nov 2016

Targeted precision medicine can eliminate cancer risk in patients with Type 2 diabetes

The links between Type 2 diabetes and cancer are complex: people suffering from diabetes mellitus essentially have a higher risk of developing cancer but, on top of that, some diabetes drugs are also suspected of increasing the risk in some cases.

8 Nov 2016

FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

28 Jul 2016

Pioglitazone effective in diabetes patients with NASH

Pioglitazone may halt the progression of nonalcoholic steatohepatitis in patients with prediabetes or Type 2 diabetes, a randomised trial shows.

28 Jun 2016

Clinical trial finds pioglitazone drug safe and effective for NASH patients

Researchers have found that an existing diabetes drug can be used to halt progression of another disease that is a leading cause of liver transplants.

21 Jun 2016

Study finds disparities in discontinuing diabetes drug rosiglitazone following FDA safety alert

Among older adults with diabetes, certain subgroups--including white patients and those with lower incomes--were slower to discontinue the diabetes drug rosiglitazone after a US Food and Drug Administration safety alert, reports a study in the April issue of Medical Care.

17 Mar 2016

Metabolic syndrome treatment benefits MS patients

Oral antidiabetic medications have beneficial anti-inflammatory effects in patients with multiple sclerosis and metabolic syndrome, providing support for a link between metabolism and autoimmunity, researchers report.

9 Mar 2016

Medical scientists examine potential new tool for helping prevent stroke, heart attack

Medical scientists just vetted a potentially powerful new tool for helping prevent stroke and heart attack. In a study recently published in the New England Journal of Medicine, researchers show that a drug reduced the risk of stroke or heart attack by almost a quarter in patients who had previously suffered a stroke or mini-stroke.

26 Feb 2016

Findings offer new approach to treating metabolic disorders

A new research study has revealed an important relationship between proteins secreted by the heart and obesity, glucose intolerance, and insulin resistance. The findings, published today in Obesity, offer a new approach to treating metabolic disorders, including type 2 diabetes, by targeting the pathway that controls the proteins' concentration in the blood.

18 Feb 2016

Tackling insulin resistance may reduce recurrence after stroke

Giving pioglitazone to stroke survivors with insulin resistance but no overt diabetes reduces their risk of having a recurrent vascular event, shows the randomised Insulin Resistance Intervention after Stroke trial.

18 Feb 2016

Pioglitazone drug may prevent recurrent stroke and heart attacks

Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes.

18 Feb 2016

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans.

11 Oct 2015

New study reveals effect of diabetes drug on bone health, benefit of exercise in mice

Inside our bones there is fat. Diabetes increases the amount of this marrow fat. And now a study from the UNC School of Medicine shows how some diabetes drugs substantially increase bone fat and thus the risk of bone fractures.

9 Sep 2015

Takeda's $2.37 billion settlement over Actos didn't attract enough claimants to participate in the deal

MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that Takeda Pharmaceutical Co.'s $2.37 billion settlement didn't attract enough claimants to participate in the deal, which said the company would fund the deal after 95% of claimants joined it.

18 Aug 2015

Takeda completes post-marketing commitment and data submission for pioglitazone containing medicines

Takeda Pharmaceutical Company Limited today announced the completion of the study to fulfill the post-marketing commitment and submissions of data to regulatory authorities from the Pan European Multi-Database Bladder Cancer Risk Characterization Study, a large (n= 112,674), multi-database retrospective matched cohort study, conducted in four European countries, for pioglitazone containing medicines, including ACTOS with up to 10 years of follow-up.

31 Jul 2015

Pioglitazone News and Research

Newer treatment for type 2 diabetes reduces liver fat in patients with NAFLD

Experimental diabetes drugs can make cancer cells vulnerable to chemotherapy agents

Diabetes patients least likely to follow medical advice regarding medication due to side effects

Researchers highlight need for paradigm shift in management of type 2 diabetes

Treating PCOS in adolescent girls may help prevent future subfertility, research suggests

Type 2 diabetes drug may someday help combat breast and ovarian cancers

Targeted precision medicine can eliminate cancer risk in patients with Type 2 diabetes

FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

Pioglitazone effective in diabetes patients with NASH

Clinical trial finds pioglitazone drug safe and effective for NASH patients

Study finds disparities in discontinuing diabetes drug rosiglitazone following FDA safety alert

Metabolic syndrome treatment benefits MS patients

Medical scientists examine potential new tool for helping prevent stroke, heart attack

Findings offer new approach to treating metabolic disorders

Tackling insulin resistance may reduce recurrence after stroke

Pioglitazone drug may prevent recurrent stroke and heart attacks

FDA awards research grants to boost product development for patients with rare diseases

New study reveals effect of diabetes drug on bone health, benefit of exercise in mice

Takeda's $2.37 billion settlement over Actos didn't attract enough claimants to participate in the deal

Takeda completes post-marketing commitment and data submission for pioglitazone containing medicines

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News